|
Published by: Visiongain
Published: Mar. 3, 2009 - 144 Pages
Table of Contents
- 1 Executive Summary
- 2 Dyslipidaemia and Coronary Heart Disease
- 2.1 Cholesterol and Triglycerides
- 2.2 Lipoproteins Transport Cholesterol and Triglycerides
- 2.3 Dyslipidaemia and Atherosclerosis
- 2.4 Cholesterol Risk Levels
- 2.5 The Fredrickson/World Health Organization (WHO) Classification of Dyslipidaemia
- 2.6 Cardiovascular Disease
- 2.7 CHD Risk Factors
- 2.8 Cholesterol Testing
- 2.9 Primary and Secondary Prevention of Atherosclerosis
- 3 Statins and Other Lipid-Lowering Drugs
- 3.1 Statins: Mechanism of Action and Types
- 3.2 Lovastatin
- 3.2.1 Lovastatin Indications
- 3.2.2 Lovastatin Brands and Generic Manufacturers
- 3.3 Simvastatin
- 3.3.1 Simvastatin Indications
- 3.3.2 Simvastatin Brands and Generic Manufacturers
- 3.4 Pravastatin
- 3.4.1 Pravastatin Indications
- 3.4.2 Pravastatin Brands and Generic Manufacturers
- 3.5 Fluvastatin
- 3.5.1 Fluvastatin Indications
- 3.5.2 Fluvastatin Brands and Generic Manufacturers
- 3.6 Atorvastatin
- 3.6.1 Atorvastatin Indications
- 3.6.2 Atorvastatin Brands and Generic Manufacturers
- 3.7 Rosuvastatin
- 3.7.1 Rosuvastatin Indications
- 3.7.2 Rosuvastatin Brands and Generic Manufacturers
- 3.8 Pitavastatin
- 3.9 Statin/Other Lipid-Lowering Drug Combinations
- 3.9.1 Lovastatin/Nicotinic Acid
- 3.9.2 Simvastatin/Nicotinic Acid
- 3.9.3 Simvastatin/Ezetimibe
- 3.9.4 Atorvastatin/Fenofibrate
- 3.9.5 Atorvastatin/Ezetimibe
- 3.9.6 Atorvastatin/Ezetimibe/Fenofibrate
- 3.10 Statin/Other Cardiovascular Drug Combinations
- 3.10.1 Caduet (Atorvastatin/Amlodipine)
- 3.10.2 Pravadual (Pravastatin/Aspirin)
- 3.10.3 Generic Statin/Other Cardiovascular Drugs
- 3.11 Other Dyslipidaemia Drugs
- 3.11.1 Anion-Exchange Resins
- 3.11.2 Ezetimibe
- 3.11.3 Fibrates
- 3.11.4 Nicotinic Acid
- 3.11.5 Omega-3-Acid Ethyl Esters
- 4 The World Statin Market
- 4.1 Statins Dominate the Lipid-Lowering Drug Market
- 4.1.1 The World Lipid-Lowering Drug Market
- 4.1.2 World Lipid-Lowering Drug Market Forecast, 2009-2024
- 4.2 The World Statin Market, 2009-2024
- 4.2.1 The World Statin Market, 2008
- 4.2.2 Scope for Further Growth: World Statin Market Forecast, 2009-2011
- 4.2.3 The Impact of Atorvastatin Genericisation on the World Statin Market, 2011-2014
- 4.2.4 Further Generic Opportunities: World Statin Market Forecast, 2014-2019
- 4.2.5 What are the Prospects for the World Statin Market from 2019 to 2024?
- 4.2.6 Statin Type Market Forecast, 2009-2024
- 4.3 The Branded and Generic Statin Markets
- 4.3.1 The Branded and Generic Statin Markets, 2008
- 4.3.2 By 2018 Sales of Generic Statins Will Exceed Branded Revenues
- 4.4 Atorvastatin
- 4.4.1 The Atorvastatin Market in 2008
- 4.4.2 Atorvastatin Market Forecast, 2009-2024
- 4.4.3 Lipitor Market Forecast, 2009-2011
- 4.4.4 The Ultimate Patent Cliff: Lipitor Market Forecast, 2011-2014
- 4.4.5 The Fate of Lipitor: Market Forecast, 2014-2024
- 4.4.6 Generic Atorvastatin Market Forecast, 2009-2024
- 4.5 Rosuvastatin
- 4.5.1 The Rosuvastatin Market in 2008
- 4.5.2 Rosuvastatin Market Forecast, 2009-2024
- 4.5.3 Bucking the Trend of Other Branded Statins: Crestor Market Forecast, 2009-2014
- 4.5.4 What are Crestor’s Prospects During 2014-2024?
- 4.5.5 Generic Rosuvastatin Market Forecast, 2009-2024
- 4.6 Simvastatin
- 4.6.1 The Simvastatin Market in 2008
- 4.6.2 Simvastatin Market Forecast, 2009-2024
- 4.6.3 Zocor Market Forecast, 2009-2024
- 4.6.4 Generic Simvastatin Market Forecast, 2009-2024
- 4.7 Pravastatin
- 4.7.1 The Pravastatin Market in 2008
- 4.7.2 Pravastatin Market Forecast, 2009-2024
- 4.7.3 Mevalotin/Pravachol Market Forecast, 2009-2024
- 4.7.4 Generic Pravastatin Market Forecast, 2009-2024
- 4.8 Fluvastatin
- 4.8.1 The Fluvastatin Market in 2008
- 4.8.2 Fluvastatin Market Forecast, 2009-2024
- 4.8.3 Lescol/Lochol Market Forecast, 2009-2024
- 4.8.4 Generic Pravastatin Market Forecast, 2009-2024
- 4.9 Pitavastatin
- 4.9.1 The Pitavastatin Market in 2008
- 4.9.2 Pitavastatin Market Forecast, 2009-2024
- 4.10 Lovastatin
- 4.10.1 The Lovastatin Market in 2008
- 4.10.2 Lovastatin Market Forecast, 2009-2024
- 4.11 Statin/Non-Statin Combination Drugs
- 4.11.1 The Statin/Non-Statin Combination Drug Market in 2008
- 4.11.2 Launch of new Statin Combination Drugs Will Drive Growth During 2009-2014
- 4.11.3 Genericisation in the Statin/Non-Statin Combination Sector, 2014-2024
- 4.11.4 Vytorin/Inegy Market Forecast, 2009-2013
- 4.11.5 Vytorin/Inegy Market Forecast, 2014-2024
- 4.11.6 Caduet Market Forecast, 2009-2024
- 4.12 Leading Statin Manufacturers
- 4.12.1 Leading Statin Manufacturers, 2008: Seven Players Control 85% of the Market
- 4.12.2 Pfizer’s Statin Revenues Forecast, 2009-2014
- 4.12.3 A New Leading Statin Manufacturer by 2013
- 4.12.4 Merck & Co./Schering-Plough Statin Revenues Forecast, 2009-2014
- 5 Issues Affecting the Statin Industry
- 5.1 SWOT Analysis of the Statin Industry
- 5.2 Patient Compliance
- 5.2.1 Patients on Statins Exhibit Poor Patient Compliance
- 5.2.2 Effective Contact Between Patients and Healthcare Practitioners is the Key to Improving Patient Compliance
- 5.2.3 Developments in Cholesterol Testing
- 5.2.4 Diagnostic Testing for Genetic Markers May Increase Patient Compliance
- 5.2.5 Increasing Use of Web-Based Information Technology Will Improve Patient Compliance
- 5.3 Generic Statins
- 5.3.1 Expected Patent Expiries in the Statin Market
- 5.3.2 Governments and Insurers Will Favour Generic Statins
- 5.4 Statin Clinical Trials
- 5.5 Safety of Statins
- 5.6 Statin OTC Switching
- 5.6.1 The Rationale for OTC Switching
- 5.6.2 Statin OTC Switching in the UK
- 5.6.3 Statin OTC Switching in the US
- 5.6.4 What are the Worldwide Prospects for Statin OTC Switching?
- 5.7 Prevalence of Coronary Heart Disease
- 5.7.1 Coronary Heart Disease is the Leading Cause of Death Worldwide
- 5.7.2 Future Projections for Prevalence of Coronary Heart Disease
- 5.7.3 The Economic Cost of Coronary Heart Disease
- 5.8 Promising Non-Statin Lipid-Lowering Pipeline
- 5.8.1 Statins Cannot Treat All Forms of Dyslipidaemia
- 5.8.2 Developments in Existing Rivals for Statins
- 5.8.2.1 Novel Nicotinic Acid Formulations
- 5.8.2.2 New Formulation of Fibrates
- 5.8.2.3 Omega-3 Fatty Acids
- 5.8.2.4 Functional Foods and Nutritional Supplements
- 5.8.3 Novel Lipid-Lowering Agents
- 5.8.3.1 CETP Inhibitors
- 5.8.3.2 Cholesterol Absorption Inhibitors
- 5.8.3.3 Antisense Oligonucleotides
- 5.8.3.4 PPAR-Alpha Agonists
- 5.8.3.5 MTP Inhibitors
- 5.8.3.6 Phospholipase A2 Inhibitors
- 5.8.3.7 Nicotinic Acid Receptor Agonists
- 5.8.3.8 Human Antibodies
- 6 Expert Opinion on Methods to Improve Patient Compliance
- 6.1 Statin Patient Compliance: Humayun J. Chaudhry, D.O., M.S., FACP, Commissioner of Health Services, Suffolk County, New York
- 6.1.1 Improving Patient Compliance in Statin Therapy
- 6.1.2 The Future of Cholesterol Testing
- 6.1.3 Web-Based Information Technology in Statin Prescribing
- 6.2 Genetic Markers to Improve Patient Compliance: Thomas White, Ph.D., Chief Scientific Officer and Vice President of Research and David P. Speechly, PhD Vice President Corporate Affairs, Celera
- 6.2.1 Patient Compliance for Statins is Poor
- 6.2.2 Genetic Markers: The KIF6 Risk Allele
- 6.2.3 Genetic Markers Could Improve Patient Compliance
- 6.2.4 Diagnostic Tests for Genetic Markers
- 6.2.5 Evidence for Genetic Marker Tests Increasing Patient Compliance
- 6.2.6 Effect of Genetic Marker Diagnostic Effects on Future Statin Prescribing Patterns
- 6.2.7 The Future of Cholesterol Testing
- 6.2.8 Effect of Genetic Markers on Clinical Trials Involving Statins
- 6.2.9 Web-Based Technologies to Improve Patient Compliance
- 7 Statin Country Markets
- 7.1 Leading Country Markets in 2008
- 7.2 Leading Country-Market Forecasts, 2009-2024
- 7.3 The US Statin Market
- 7.3.1 The US Statin Market in 2008
- 7.3.2 US Statin Market Forecast, 2009-2014
- 7.3.3 US Statin Market Forecast, 2014-2024
- 7.4 The Japanese Statin Market
- 7.4.1 The Japanese Statin Market in 2008
- 7.4.2 Japanese Statin Market Forecast, 2009-2024
- 7.5 The Canadian Statin Market
- 7.6 European Statin Markets
- 7.7 Emerging Statin Markets: China and India
- 8 The Statin Pipeline
- 8.1 The Statin Pipeline Lacks New Products
- 8.2 New Statins and Statin Combination Drugs in Development
- 8.2.1 Crestor/TriLipix
- 8.2.2 Crestor for Patients with Elevated CRP
- 8.2.3 Simvastatin and Nicotinic Acid/Laropiprant
- 8.2.4 Pravastatin and Fenofibrate Combination Therapy
- 8.2.5 Simvastatin and Fenofibrate Combination Therapy
- 8.2.6 Vytorin for Kidney Disease and Acute Coronary Syndrome.
- 8.2.7 Simvastatin/Rosiglitazone
- 8.2.8 PPD Statin/RBx 10558
- 8.2.9 Simvastatin/Aspirin/Lisinopril/Hydrochlorothiazide
- 8.2.10 Simvastatin/Aspirin/Ramipril
- 8.2.11 NCX 6560
- 8.2.12 Atorvastatin/Ezetimibe
- 9 Conclusions
- 9.1 The Statin Market in 2008
- 9.2 Future Challenges for the Statin Industry
- 9.3 Rise of the Generics: World Statin Market Forecast, 2009-2024
- 9.4 Leading Statin Manufacturers and Country Markets
- List of Tables
- Table 2.1 Risk Levels for Total Cholesterol
- Table 2.2 Risk Levels for LDL Cholesterol
- Table 2.3 Risk Levels for HDL Cholesterol
- Table 2.4 Risk Levels for Triglycerides
- Table 2.5 The Fredrickson/WHO Classification of Dyslipidaemia
- Table 3.1 Leading Generic Lovastatin Manufacturers
- Table 3.2 Leading Generic Simvastatin Manufacturers
- Table 3.3 Leading Generic Pravastatin Manufacturers
- Table 3.4 Branded Fibrates
- Table 3.5 Leading Prescription Omega-3 Acid Products
- Table 4.1 World Lipid-Lowering Drug Market, 2008
- Table 4.2 Non-Statin Lipid-Lowering Drug Market, 2008
- Table 4.3 World Lipid-Lowering Drug Market Forecasts, 2009-2014
- Table 4.4 World Lipid-Lowering Drug Market Forecasts, 2015-2024
- Table 4.5 Leading Statin Types and Brands, 2008
- Table 4.6 Statin Type Market Forecasts, 2009-2014
- Table 4.7 Statin Type Market Forecasts, 2015-2024
- Table 4.8 The Branded and Generic Statin Markets, 2008
- Table 4.9 Branded and Generic Statin Market Forecasts, 2009-2014
- Table 4.10 Branded and Generic Statin Market Forecasts, 2015-2024
- Table 4.11 Atorvastatin Market, 2008
- Table 4.12 Atorvastatin Drugs Forecasts, 2009-2014
- Table 4.13 Atorvastatin Drugs Forecasts, 2015-2024
- Table 4.14 Rosuvastatin Market, 2008
- Table 4.15 Rosuvastatin Drugs Forecasts, 2009-2014
- Table 4.16 Rosuvastatin Drugs Forecasts, 2015-2024
- Table 4.17 Simvastatin Market, 2008
- Table 4.18 Simvastatin Drugs Forecasts, 2009-2014
- Table 4.19 Simvastatin Drugs Forecasts, 2015-2024
- Table 4.20 Pravastatin Market, 2008
- Table 4.21 Pravastatin Drugs Forecasts, 2009-2014
- Table 4.22 Pravastatin Drugs Forecasts, 2015-2024
- Table 4.23 Fluvastatin Market, 2008
- Table 4.24 Fluvastatin Drugs Forecasts, 2009-2014
- Table 4.25 Fluvastatin Drugs Forecasts, 2015-2024
- Table 4.26 Pitavastatin Drugs Forecasts, 2009-2014
- Table 4.27 Pitavastatin Drugs Forecasts, 2015-2024
- Table 4.28 Lovastatin Drugs Forecasts, 2009-2014
- Table 4.29 Lovastatin Drugs Forecasts, 2015-2024
- Table 4.30 Statin and Statin/Non-Statin Combination Drug Sales, 2008
- Table 4.31 Statin/Non-Statin Combination Drug Market, 2008
- Table 4.32 Statin/Non-Statin Combination Drugs Forecasts, 2009-2014
- Table 4.33 Statin/Non-Statin Combination Drugs Forecasts, 2015-2024
- Table 4.34 Leading Statin Manufacturers, 2008
- Table 4.35 Leading Statin Manufacturers’ Revenue Forecasts, 2009-2014
- Table 5.1 SWOT Chart for the Statins Industry, 2009-2024
- Table 5.2 Expected Statin Patent Expiry Dates, 2009-2024
- Table 5.3 Novel Lipid-Lowering Drugs in Development
- Table 7.1 Leading Statin Country Markets, 2008
- Table 7.2 Leading Statin Country-Market Forecasts, 2009-2014
- Table 7.3 Leading Statin Country Market Forecasts, 2015-2024
- Table 8.1 The Statins Pipeline
- List of Figures
- Figure 4.1 World Lipid-Lowering Drug Market, 2008
- Figure 4.2 World Lipid-Lowering Drug Market Forecast, 2009-2024
- Figure 4.3 Statin Type Market Share, 2008
- Figure 4.4 Leading Statin Brand Market Share, 2008
- Figure 4.5 World Statin Market Forecast, 2009-2024
- Figure 4.6 Statin Type Market Forecast, 2009-2024
- Figure 4.7 Statin Type Market Share, 2014
- Figure 4.8 Statin Type Market Share, 2019
- Figure 4.9 Statin Type Market Share, 2024
- Figure 4.10 Branded and Generic Statin Market Forecasts, 2009-2024
- Figure 4.11 Atorvastatin Drugs Forecasts, 2009-2024
- Figure 4.12 Rosuvastatin Drugs Forecasts, 2009-2024
- Figure 4.13 Simvastatin Drugs Forecasts, 2009-2024
- Figure 4.14 Pravastatin Drugs Forecasts, 2009-2024
- Figure 4.15 Fluvastatin Drugs Forecasts, 2009-2024
- Figure 4.16 Pitavastatin Drugs Forecasts, 2009-2024
- Figure 4.17 Lovastatin Drugs Forecasts, 2009-2024
- Figure 4.18 Statin Combination Drugs Forecasts, 2009-2024
- Figure 4.19 Leading Statin Manufacturers, 2008
- Figure 4.20 Leading Statin Manufacturers’ Revenue Forecasts, 2009-2014
- Figure 7.1 Statin Market Share by Country, 2008
- Figure 7.2 Statin Market Share by Country, 2014
- Figure 7.3 Statin Market Share by Country, 2019
- Figure 7.4 Statin Market Share by Country, 2024
- Figure 7.5 US Statin Market Forecast, 2009-2024
- Figure 7.6 Japanese Statin Market Forecast, 2009-2024
- Figure 7.7 Canadian Statin Market Forecast, 2009-2024
- Figure 7.8 French, UK, Chinese and Indian Statin Market Forecasts, 2009-2024
- Figure 9.1 World Statin Market Forecast, 2009-2024
AbstractThe world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently, those drugs are one of the most widely-prescribed and most lucrative sectors of the pharmaceutical industry, with total revenues exceeding $26 billion in 2008. Importantly, the world statins market is poised to undergo a period of rapid and dynamic change, with the generic statin sector growing particularly strongly in the years ahead. When will annual sales of generic statins exceed those of branded statins? Which branded statin will continue to achieve year-on-year sales growth during the coming waves of generic competition? Statins: The World Market, 2009-2024 answers these vital questions - amongst others - and provides the essential information that you need to take advantage of opportunities in the changing statin drugs market from 2009 onwards.
Statins: The World Market, 2009-2024 provides a comprehensive analysis of the world statins market, compiled using a wealth of research tools - including interviews with key opinion-leaders, examination of commercial databases, company reports, policy documents, industry news and filings. This original study provides extensive sales forecasting, market shares present and future, informed opinion, as well as detailed analysis of unmet needs, pipeline developments and commercial opportunities for statin drugs.
Highlights of Statins: The World Market, 2009-2024 include:
- Forecasts to 2024 for the overall world statin market, the generic statin market, the branded statin market and the dyslipidaemia market, including all statin types, the leading statin brands, leading manufacturers, country markets and combination statin drugs
- Interviews with key-opinion leaders in the field
- Examination of strengths, weakness, opportunities and threats facing major stakeholders in the sector - the market drivers and restraints
- Analysis and forecasts for the leading statin markets in the US, Japan and Canada, together with leading European and emerging national markets
- Analysis of the R&D pipeline for new statins, as well as other lipid-lowering drug types.
With full market forecasts for all the major generic statins, this new visiongain report reveals the significant commercial opportunities in new sectors of the statin market. However, significant opportunities exist for original branded products too. With relatively few single statins currently in development, new product developments in statins will mainly focus on statin combination drugs, visiongain predicts. In addition, strong growth in the statins sector will occur in emerging national markets - most notably in China and India - driving global sales. There are vast and expanding existing and potential patient populations for those drugs worldwide.
Importantly, there are opportunities for companies to raise sales by maximising patient compliance and accessing new patient groups. Statins: The World Market, 2009-2024 examines strategies for increasing patient compliance there. The report has detailed interviews with key-opinion leaders in this important field. Full interview transcripts are provided - you will not find this information anywhere else.
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for statins from 2009-2024, including predicted revenues, growth rates, market shares and other key metrics
- To identify key pipeline developments and up-and-coming products, both in the field of statins, and for other lipid-lowering therapies
- To discover the drivers, restraints, competition and opportunities influencing the global statins market -for leading brands, generics and statin combination drugs
- To receive forecasts for leading statin country markets and major emerging markets for statin drugs, including China and India
- To find out where that market sector is heading - both technologically and commercially - from the present onwards.
Statins: The World Market, 2009-2024 is essential reading for everybody involved in the statins market, revealing prospects for both existing competitors and potential market entrants from the present onwards.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
I have noted this in the comments for this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
